Limited Influence of P-Glycoprotein on Small-intestinal Absorption of Cilostazol, a High Absorptive Permeability Drug

Journal of Pharmaceutical Sciences

Volumn 92, Issue 11, 2003, Pages 2249-2259

  Toyobuku, Hidekazu ^a   Tamai, Ikumi ^a,b   Ueno, Kazuyuki ^c   Tsuji, Akira ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b TOKYO UNIVERSITY OF SCIENCE   (Japan)

^c NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

Caco 2 cells; Cilostazol; Influx; Intestinal absorption; P glycoprotein; Secretion; Transporter

Indexed keywords

CARRIER PROTEIN; CILOSTAZOL; DAUNORUBICIN; GLYCOPROTEIN P; RIFAMPICIN;

ANIMAL CELL; ANIMAL TISSUE; APICAL MEMBRANE; ARTICLE; ASSAY; BASOLATERAL MEMBRANE; CELL STRAIN CACO 2; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG ACCUMULATION; DRUG PENETRATION; HUMAN; HUMAN CELL; ILEUM; INTESTINE SECRETION; MALE; NONHUMAN; RAT; SMALL INTESTINE ABSORPTION; TEMPERATURE DEPENDENCE; TRANSCYTOSIS;

EID: 0242290406     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.10490     Document Type: Article

References (39)

1. Wacher VJ, Silverman JA, Zhang Y, Benet LZ. 1998. Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J Pharm Sci 87:1322-1330.
2. Chen CJ, Chin JE, Ueda K, Clark DP, Pastan I, Gottesman MM, Roninson IB. 1986. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 47:381-389.
3. Ueda K, Clark DP, Chen CJ, Roninson IB, Gottesman MM, Pastan I. 1987. The human multidrug resistance (mdr1) gene. cDNA cloning and transcription. J Biol Chem 262:505-508.
4. Tsuji A, Tamai I. 1997. Blood-brain barrier function of P-glycoprotein. Adv Drug Del Rev 25:287-298.
5. Schinkel AH, Wagenaar E, Van Deemter L, Mol CA, Borst P. 1995. Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest 96:1698-1705.
6. van Asperen J, Schinkel AH, Beijnen JH, Nooijen WJ, Borst P, van Tellingen O. 1996. Altered pharmacokinetics of vinblastine in mdr1a P-glycoprotein-deficient mice. J Natl Cancer Inst 88:994-999.
7. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U. 2000. Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 97:3473-3478.
8. Kimura Y, Tani T, Kanbe T, Watanabe K. 1985. Effect of cilostazol on platelet aggregation and experimental thrombosis. Arzneimittelforschung 35:1144-1149.
9. Dawson DL, Cutler BS, Meissner MH, Strandness DE Jr. 1998. Cilostazol has beneficial effects in treatment of intermittent claudication: Results from a multicenter, randomized, prospective, double-blind trial. Circulation 98:678-686.
10. Tanaka K, Gotoh F, Fukuuchi Y, Amano T, Uematsu D, Kawamura J, Yamawaki T, Itoh N, Obara K, Muramatsu K. 1989. Effects of a selective inhibitor of cyclic AMP phosphodiesterase on the pial microcirculation in feline cerebral ischemia. Stroke 20:668-673.
11. Tanabe Y, Ito E, Nakagawa I, Suzuki K. 2001. Effect of cilostazol on restenosis after coronary angioplasty and stenting in comparison to conventional coronary artery stenting with ticlopidine. Int J Cardiol 78:285-291.
12. Ishida S, Morii M, Ueno K, Takada M, Sakata T, Okamoto A, Kobayashi J, Monta O, Koizumi N, Sasako Y, Shibakawa M. 2000. Studies on factor affecting pharmacokinetics of cilostazol and pharmacokinetics-pharmacodynamics analysis based platelet aggregation. Jpn J Hosp Pharm 26:264-272.
13. Bramer SL, Forbes WP, Mallikaarjun S. 1999. Cilostazol pharmacokinetics after single and multiple oral doses in healthy males and patients with intermittent claudication resulting from peripheral arterial disease. Clin Pharmacokinet 37:1-11.
14. Tanigawara Y, Okamura N, Hirai M, Yasuhara M, Ueda K, Kioka N, Komano T, Hori R. 1992. Transport of digoxin by human P-glycoprotein expressed in a porcine kidney epithelial cell line (LLC-PK1). J Pharmacol Exp Ther 263:840-845.
15. Ueda K, Okamura N, Hirai M, Tanigawara Y, Saeki T, Kioka N, Komano T, Hori R. 1992. Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. J Biol Chem 267:24248-24252.
16. Tamai I, Takanaga H, Maeda H, Yabuuchi H, Sai Y, Suzuki Y, Tsuji A. 1997. Intestinal brush-border membrane transport of monocarboxylic acids mediated by proton-coupled transport and anion antiport mechanisms. J Pharm Pharmacol 49:108-112.
17. Kusunoki N, Takara K, Tanigawara Y, Yamauchi A, Ueda K, Komada F, Ku Y, Kuroda Y, Saitoh Y, Okumura K. 1998. Inhibitory effects of a cyclosporin derivative, SDZ PSC 833, on transport of doxorubicin and vinblastine via human P-glycoprotein. Jpn J Cancer Res 89:1220-1228.
18. Tsuji A, Takanaga H, Tamai I, Terasaki T. 1994. Transcellular transport of benzoic acid across Caco-2 cells by a pH-dependent and carrier-mediated transport mechanism. Pharm Res 11:30-37.
19. Bradford MM. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye bind-ing. Anal Biochem 72:248-254.
20. Tanaka K, Hirai M, Tanigawara Y, Ueda K, Takano M, Hori R, Inui K. 1997. Relationship between expression level of P-glycoprotein and daunorubicin transport in LLC-PK1 cells transfected with human MDR1 gene. Biochem Pharmacol 53:741-746.
21. Schuetz EG, Beck WT, Schuetz JD. 1996. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol 49:311-318.
22. Makhey VD, Guo A, Norris DA, Hu P, Yan J, Sinko PJ. 1998. Characterization of the regional intestinal kinetics of drug efflux in rat and human intestine and in Caco-2 cells. Pharm Res 15:1160-1167.
23. Naruhashi K, Tamai I, Inoue N, Muraoka H, Sai Y, Suzuki N, Tsuji A. 2001. Active intestinal secretion of new quinolone antimicrobials and the partial contribution of P-glycoprotein. J Pharm Pharmacol 53:699-709.
24. Tamura S, Ohike A, Ibuki R, Amidon GL, Yamashita S. 2002. Tacrolimus is a class II low-solubility high-permeability drug: The effect of P-glycoprotein efflux on regional permeability of tacrolimus in rats. J Pharm Sci 91:719-729.
25. Tian R, Koyabu N, Takanaga H, Matsuo H, Ohtani H, Sawada Y. 2002. Effects of grapefruit juice and orange juice on the intestinal efflux of P-glycoprotein substrates. Pharm Res 19:802-809.
26. Naruhashi K, Tamai I, Inoue N, Muraoka H, Sai Y, Suzuki N, Tsuji A. 2002. Involvement of multidrug resistance-associated protein 2 in intestinal secretion of grepafloxacin in rats. Antimicrob Agents Chemother 46:344-349.
27. Chianale J, Vollrath V, Wielandt AM, Miranda S, Gonzalez R, Fresno AM, Quintana C, Gonzalez S, Andrade L, Guzman S. 1995. Differences between nuclear run-off and mRNA levels for multidrug resistance gene expression in the cephalocaudal axis of the mouse intestine. Biochim Biophys Acta 1264:369-376.
28. Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM, Pastan I. 1987. Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 84:265-269.
29. Geick A, Eichelbaum M, Burk O. 2001. Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem 276:14581-14587.
30. Greiner B, Eichelbaum M, Fritz P, Kreichgauer HP, von Richter O, Zundler J, Kroemer HK. 1999. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 104:147-153.
31. Tamai I, Saheki A, Saitoh R, Sai Y, Yamada I, Tsuji A. 1997. Nonlinear intestinal absorption of 5-hydroxytryptamine receptor antagonist caused by absorptive and secretory transporters. J Pharmacol Exp Ther 283:108-115.
32. Abbas R, Chow CP, Browder NJ, Thacker D, Bramer SL, Fu CJ, Forbes W, Odomi M, Flockhart DA. 2000. In vitro metabolism and interaction of cilostazol with human hepatic cytochrome P450 isoforms. Hum Exp Toxicol 19:178-184.
33. Toth GG, Kloosterman C, Uges DR, Jonkman MF. 1999. Pharmacokinetics of high-dose oral and intravenous dexamethasone. Ther Drug Monit 21:532-535.
34. Iisalo E. 1977. Clinical pharmacokinetics of digoxin. Clin Pharmacokinet 2:1-16.
35. Efthymiopoulos C, Bramer SL, Maroli A. 1997. Pharmacokinetics of grepafloxacin after oral administration of single and repeat doses in healthy young males. Clin Pharmacokinet 33:1-8.
36. Yamaguchi H, Yano I, Saito H, Inui K. 2002. Pharmacokinetic role of P-glycoprotein in oral bioavailability and intestinal secretion of grepafloxacin in vivo. J Pharmacol Exp Ther 300:1063-1069.
37. Akiyama H, Kudo S, Shimizu T. 1985. The metabolism of a new antithrombotic and vasodilating agent, cilostazol, in rat, dog and man. Arzneimittelforschung 35:1133-1140.
38. Artursson P, Palm K, Luthman K. 2001. Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv Drug Del Rev 46:27-43.
39. Lentz KA, Polli JW, Wring SA, Humphreys JE, Polli JE. 2000. Influence of passive permeability on apparent P-glycoprotein kinetics. Pharm Res 17:1456-1460.